Cytokine Based Therapies and Inhibitors is a branch of science combining biology and engineering. It brings together several disciplines from both these fields such as genetic engineering, biotechnology, molecular engineering, computer engineering and evolutionary biology. In Cytokine Based Therapies and Inhibitors, these disciplines are applied to build artificial biological systems to be used in engineering, research, and medical applications.
Cytokine Based Therapies and Inhibitors Market was worth USD xx billion in 2018 and is projected to grow at a CAGR of xx%, to reach USD xx billion by 2023.
To achieve the intended biological system through DNA modification or sequencing, technology plays a major role. Computer-aided designs are needed to model the designs accurately and technologies which can read and write DNA are highly useful. By combining advances in biology with the modern technologies, organisms can be designed to produce several chemicals or enzymes or biofuels.
Increasing expenditure on research and development of biotechnology and pharmaceutical companies, increasing demand for genetically modified crops and major technological advancements in DNA studies are the major factors driving the market growth. Increasing demand for alternative fuels such as biofuels and growing popularity for protein therapeutics are also expected to propel the market growth. However, ethical concerns regarding the biosafety and biosecurity and stringent regulations are hindering the growth of the market.
The Cytokine Based Therapies and Inhibitors market is categorized by type, therapeutic application and region. Based on type of cytokines, the market is categorized into Interleukins, Tumor necrosis factor, epidermal growth factor, Interferon and Chemokine. Xeno nucleic acid is the largest market segment due to the high demand for synthetic alternatives to nucleic acids DNA and RNA. On the basis of therapeutic application, the market is categorized into Inflammatory and immune disorders, Cancer & malignancies, Infectious diseases and others. Enabled technologies are expected to be the largest market segment and enabling technologies are the fastest growing market segment due to several ongoing researches which might result in innovative technologies or ideas for application of Cytokine Based Therapies and Inhibitors. Enabling technologies are again categorized into Gene Synthesis, Cloning and Sequencing, Genome Engineering, Bioinformatics, Nanotechnology, Site-Directed Mutagenesis, Microfluidics and Measurement and Modeling. Gene synthesis is the major market segment in enabling technologies due to the increasing demand for protein synthesis through synthetic means. Enabled technologies are further categorized into Next-Generation Sequencing and Pathway Engineering.
On the basis of region, the global Cytokine Based Therapies and Inhibitors market is categorized into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America leads the Cytokine Based Therapies and Inhibitors market due to the presence of a large number of companies in Cytokine Based Therapies and Inhibitors and increasing investments from the government. Asia Pacific is the fastest growing market segment due to the growing awareness and increasing collaborations with western companies in China and also due to the well-established biotechnology industries in Japan.
Some of the major players in Cytokine Based Therapies and Inhibitors market are GlaxoSmithKline LLC, AbbVie Inc., Eli Lilly and Company, Genentech, Inc., Immunochemistry Technologies LLC, Roche Diagnostics, Novartis, Merck Sharp & Dohme Corp., Johnson & Johnson and Amgen Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Interleukins
5.1.3 Tumor necrosis factor
5.1.4 Epidermal growth factor
5.1.5 Interferon
5.1.6 Chemokine
5.1.7 Y-o-Y Growth Analysis, By Type
5.1.8 Market Attractiveness Analysis, By Type
5.1.9 Market Share Analysis, By Type
5.2 Therapeutic Application
5.2.1 Introduction
5.2.2 Inflammatory and immune disorders
5.2.3 Cancer and malignancies
5.2.4 Infectious diseases
5.2.5 Others
5.2.6 Y-o-Y Growth Analysis, By Therapeutic Application
5.2.7 Market Attractiveness Analysis, By Therapeutic Application
5.2.8 Market Share Analysis, By Therapeutic Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Therapeutic Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Therapeutic Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Therapeutic Application
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 GlaxoSmithKline LLC
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AbbVie Inc.
8.3 Eli Lilly and Company
8.4 Genentech, Inc
8.5 Immunochemistry Technologies LLC
8.6 Roche Diagnostics
8.7 Novartis
8.8 Merck Sharp & Dohme Corp
8.9 Johnson & Johnson
8.10 Amgen Inc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
